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Abstract
Background: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability
has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical
forms have not been compared.
Methods: In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived
from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA
compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y)
were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed
pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA
in the applied supplements was analyzed.
Results: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC0-72 h:
80.03 ± 34.71%*h), followed by fish oil rTAG (mean AUC0-72 h: 59.78 ± 36.75%*h) and EE (mean AUC0-72 h:
47.53 ± 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the
sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the
differences in EPA bioavailability. Statistical pair-wise group comparison’s revealed a trend (p = 0.086) between
rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total
EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not
contain any free FA.
Conclusion: Further studies with a larger sample size carried out over a longer period are needed to substantiate
our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of
LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have
a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and
taken into consideration in future trials.
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Background
Scientific and regulatory bodies recommend an increased
intake of EPA+DHA for cardiovascular prevention or
during pregnancy [1-3]. Because a number of large inter-
vention trials were conducted using 1 g EPA+DHA ethyl-
ester (EE)/d, the American Heart Association recommends
1 g EPA+DHA/d in fish or as capsules [4]. As a result of a
consensus conference, increasing DHA intake by 200 mg/
d during pregnancy has been recommended [2]. However,
in natural fish oil, EPA+DHA are bound in triacylglycer-
ides (TAG) whereas many fish oil capsules contain the
fatty acids (FA) bound in EE or re-esterified TAG (rTAG).
Implicitly, the recommendations assume that different
chemical forms of EPA and DHA have comparable
bioavailability.
Recently, we demonstrated that a six-month supple-
mentation of identical doses of EPA+DHA (1.67 g/d)
leads to a faster and higher increase of the omega-3
index - the percentage of EPA and DHA in red cell mem-
branes reflecting the long-term intake and n-3 FA status
of an individual [5] - when consumed as rTAG than
when consumed as EE [6]. After six months, the omega-3
index increased significantly higher in the rTAG-group
than in the EE-group [197% vs. 171% [p < 0.01]). Our
results were in line with data from a short-term study of
two weeks duration measuring the FA compositions of
serum cholesterol-esters, TAG and phospholipids (PL):
relative bioavailability of EPA+DHA from rTAG was
superior (124%) compared with cod liver oil (100%),
whereas the bioavailability from EE was inferior (73%)
[7]. Bioavailability of free FA and natural fish oil TAG
was similar to cod liver oil [7]. Smaller trials carried out
earlier had inconsistent results [8-13]. A direct compari-
son of krill oil to fish oil TAG noted similar changes in
plasma FA, while fish oil reduced the blood pressure and
krill oil did not [14]. In another comparison, the dose of
EPA+DHA in krill oil was 62.8% of that in fish oil, but
similar changes in plasma EPA+DHA and of a lipid panel
were observed [15].
To the best of our knowledge, no study has attempted
to compare the bioavailability of identical doses of EPA+
DHA from krill oil (largely PL) to that of other chemical
forms. Therefore, in the present study, we compared single
doses of three commonly available chemical forms of EPA
and DHA, rTAG, EE and PL, in a double-blinded cross-
over design. We used changes of the FA compositions in
plasma PL within 72 h following the ingestion of a single
dose of EPA+DHA as a proxy for bioavailability. The
crossover design was considered as particularly suitable to
assess the comparative bioavailability of EPA + DHA from
n-3 FA formulations, since inter-individual variability,
which is frequently observed after the administration of
n-3 FA supplements, can be minimized. Additionally, we
analyzed the proportion of free EPA and DHA in the used
supplements, since free long-chain (LC) FA are known to
possess a greater bioavailability compared to other n-3 FA
formulations.
Methods
Subjects and study design
Healthy young men were recruited from the general
population by an advertisement. The inclusion criteria
for participating in the study were male gender, an age
between 20 and 50 years and a body mass index (BMI)
between 20 and 28 kg/m2. Diagnosis or suspicion of gas-
trointestinal disorders, high intake of oily fish (> 2 times
per week), intake of dietary supplements (e.g. n-3 FA,
phytosterols, polyglucosamin) and intake of lipid-lower-
ing drugs two weeks before and during intervention
were defined as exclusion criteria. Inclusion and exclu-
sion criteria were assessed via structured questionnaires
before the intervention period and on the intervention
days. Subjects were instructed to avoid foods rich in n-3
FA to minimize intake variability. Restricted foods
included fish, seafood, and vegetable oil.
Twelve male volunteers (age 31 ± 5 years) were given
one of three highly purified EPA and DHA rich oils in a
crossover design, each intervention day separated by
14 days wash-out period. The allocation of subjects to dif-
ferent treatments was carried out in a randomized order
to avoid treatment order effects. The three different sup-
plements were: fish oil capsules consisting of EPA+DHA
as rTAG, fish oil capsules consisting of EPA+DHA as EE
and krill oil capsules consisting of EPA+DHA mainly as
PL. The two fish oil supplements (rTAG and EE) were
provided by Dr. Loges + Co. GmbH, Winsen, Germany,
while the krill oil was a commercially available supplement
(NKO®) from Neptune Technologies & Bioressources
Inc., Québec, Canada.
During every intervention day, each subject ingested
the allocated capsules at 7:00 a.m. after an overnight fast.
Capsules were given with a standardized breakfast that
contained 30.1 g of fat, 29.6 g of protein, 67.9 g of carbo-
hydrate, and 2.7 MJ of energy. The total fat intake (break-
fast + capsules) was 33.5 g for the rTAG and the EE
treatment and 37.1 g for the krill oil treatment. During
the intervention day, subjects consumed standardized
meals over 24 h, which were personally adjusted accord-
ing to weight. Meals were consumed 3, 5, 7, 10, 12, and
24 hours after capsule ingestion. Blood samples were
taken initially (predose at baseline) and 2, 4, 6, 8, 24, 48,
and 72 h after the intake of the capsules. Volunteers were
only allowed to drink water during the intervention day.
This investigator initiated study was designed and con-
ducted in accordance with the principles of the GCP
Guidelines laid down in the Declaration of Helsinki, and
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was approved by Freiburger Ethik-Komission Interna-
tional, Germany. Written informed consent was obtained
from all subjects. The trial was registered at Clinical-
Trials.gov (ID: NCT01214278).
Composition of study supplements and total EPA+DHA
intake
The composition and amounts of the supplements are
given in Table 1. While the total EPA+DHA intake was
1680 mg for all three treatments, there were marginal dif-
ferences in the individual intake of EPA and DHA between
the three treatments. The total EPA intake was 1080 mg
for the rTAG and EE treatment and 1050 mg for the krill
oil treatment, while the total DHA intake was 672 mg for
the rTAG and EE treatment and 630 mg for the krill oil
treatment.
Quantitative analysis of free FA in fish and krill oil
samples
Analysis of free FA (FFA) were performed in an external
laboratory (Lipidomix GmbH, Berlin, Germany). 10 mg
oil of each product sample was dissolved in 1 mL etha-
nol. FA were measured through reversed phase HPLC-
Mass spectrometry with electrospray ionization in nega-
tive mode. The Agilent 1200SL/6460 system, operated
in MS2Scan mode, was equipped with a Zorbax SB-C18
30 × 2.1 mm, 1.8 μm column, while Methanol/10 mM
ammonium acetate in water was used as solvent. FA
were identified by comparison with a FA standard mix-
ture. The calibrated range was 1-1000 mg of each FA.
Anthropometric measurements and blood sampling
Subjects were examined by trained professionals accord-
ing to standardized methods at the Institute of Food
Science and Human Nutrition of Leibniz University
Hannover, Germany. Body weight was measured using a
calibrated scale (SECA, Hamburg, Germany), body
height was surveyed via tape measure and BMI was cal-
culated as weight (kg)/height (m2). Body weight and
height were measured each intervention day. The blood
samples were drawn using EDTA-monovettes (Sarstedt,
Germany).
Plasma phospholipid fatty acid analyses in blood samples
For plasma preparation, blood samples were directly centri-
fuged (2000 g, 10 min, 10°C), and plasma taken off. Pre-
pared samples were stored at -70°C and shipped on ice to
the laboratory (Omegametrix GmbH, München, Germany)
after completion of the study. Plasma PL FA composition
(primary endpoint) was analyzed as described previously
[16] with minor modifications. Lipids were extracted, and
PLs purified by use of a Sep-Pak C-18 mini cartridge
(Waters, Eschborn, Germany). FA methyl esters were
formed by acid hydrolysis, and were analyzed by capillary
gas-liquid chromatography on a GC2010 Gas Chromato-
graph (Shimadzu, Duisburg, Germany) equipped with a
SP2560, 100-m column (Supelco, Bellefonte, PA) using
hydrogen as carrier gas. FA were identified by comparison
with a FA standard mixture. Results are expressed as % of
total FA in plasma PL.
Mathematical and statistical analyses
Data are presented as mean ± standard deviation for con-
tinuous variables, and number of subjects (n) and percen-
tage (%), respectively for categorical variables. All plasma
levels were corrected to baseline levels. Areas under the
curve (AUC) of EPA+DHA were calculated for each
person during each intervention period according to the
trapezoidal rule. Time (tmax) to maximum serum concen-
trations (cmax) were identified by visual inspection of the
data. Data was found to be normally distributed using the
Kolmogorov-Smirnov test, and therefore parametric tests
were used for the statistical analyses. AUC, cmax and tmax
were compared by ANOVA with post hoc testing accord-
ing to Bonferroni’s method. Values of p ≤ 0.05 were con-
sidered to be statistically significant, while a trend was
defined as p ≤ 0.1. Statistical analyses were carried out




Twelve healthy males participated in this study. Their
mean age was 31 ± 5 years, mean height was 1.84 ±
0.09 m, mean weight was 83.3 ± 9.4 kg, and mean BMI
Table 1 Dose and composition of capsules administered in the three study supplements
rTAG EE Krill oil
per capsule per day
(4 capsules)
per capsule per day
(4 capsules)
per capsule per day
(14 capsules)
EPA 252 mg 1008 mg 252 mg 1008 mg 75 mg 1050 mg
DHA 168 mg 672 mg 168 mg 672 mg 45 mg 630 mg
EPA+DHA 420 mg 1680 mg 420 mg 1680 mg 120 mg 1680 mg
total n-3 FA 504 mg 2016 mg 504 mg 2016 mg 150 mg 2100 mg
total fat 850 mg 3400 mg 850 mg 3400 mg 500 mg 7000 mg
Abbreviations: rTAG: re-esterified triacylglycerides; EE: ethyl esters.
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was 24.6 ± 2.2 kg/m2. Due to the crossover design base-
line levels were not significantly different between the
treatments.
EPA and DHA in plasma phospholipids
The amounts of EPA and DHA, as well as total n-3 FA,
in plasma PL (mean ± standard deviation) at baseline
and 24 h after ingestion of the different marine n-3 FA
formulations are given in Table 2. The n-3 FA concen-
trations in plasma PL were at their highest after 24 h.
Differences in plasma PL levels between rTAG, EE and
krill oil are demonstrated in Table 3, which shows the
EPA, DHA and total n-3 FA gradients as AUC0-72, cmax
and tmax values.
The comparison of AUC0-72 values shows that the
EPA, DHA, EPA+DHA and total n-3 FA levels in
plasma PL were higher after the krill oil treatment com-
pared to rTAG and EE. Furthermore the DHA, EPA
+DHA and total n-3 FA uptake from the rTAG formu-
lation was higher compared to EE, while the EPA uptake
was higher after EE treatment than after rTAG treat-
ment. However, due to high standard deviation values,
the observed differences were not significant. A trend
(p = 0.057) was observed for EPA. Post-hoc tests
revealed a trend (p = 0.086) between rTAG and krill oil.
The cmax levels for EPA+DHA differed significantly
(p = 0.039), although statistical pair-wise group compar-
ison showed only significant differences between krill oil
and EE (p = 0.034). No significant differences in cmax
levels were observed for EPA, DHA and total n-3 FA
between the treatments. However, a trend (p = 0.095) in
cmax levels was observed for EPA. Post-hoc tests
revealed a trend (p = 0.094) between krill oil and EE.
No significant differences in tmax levels were observed
between the treatments (rTAG, EE and krill oil).
Figure 1 illustrates the time-dependent courses of the
mean percent change of EPA, DHA, EPA+DHA, and
total n-3 FA levels in plasma PL from baseline to 72 h
post-consumption. Each n-3 FA formulation produced
an increase in EPA, DHA and total n-3 FA content in
plasma PL, except for DHA after EE treatment. In the
latter treatment the DHA values dropped a priori and
reached a positive range approximately 12 h after inges-
tion of the supplement.
Proportion of free FA in fish and krill oil samples
While no FFA were determined in the two fish oil sam-
ples rTAG and EE, the krill oil sample contained 33 mg
EPA/g (22% of the total EPA amount) and 19 mg DHA/g
(21% of the total DHA amount).
Discussion
In a randomized crossover study in healthy volunteers,
we observed the highest incorporation of EPA, DHA
and total n-3 FA into plasma PL after the ingestion of
krill oil (PL and FFA), followed by rTAG derived from
fish oil, again followed by EE. Due to high standard
deviation values, the differences were not significant.
However, a trend was observed for EPA.
Few studies investigated differences in EPA+DHA bioa-
vailability between krill oil and fish oil TAG. One rando-
mized, double-blind, placebo-controlled trial over
4 weeks compared differences in EPA+DHA uptake
between krill oil and fish oil TAG by analyzing total
plasma FA composition [14]. While subjects on krill oil
received 216 mg/d EPA and 90 mg/d DHA, subjects on
menhaden oil received 212 mg/d EPA and 178 mg/d
DHA. Total plasma EPA and DHA levels in both n-3 FA
groups increased similarly. Consistent with our results,
the EPA uptake from krill oil was higher compared to
menhaden oil. On the other hand, the DHA uptake from
menhaden oil was greater than in the krill oil group,
probably due to the higher dose given. In contrast to the
present study, doses of n-3 FA were not well matched,
obviating strong conclusions about bioavailability. Of
note, systolic blood pressure declined only in the menha-
den oil group, possibly reflecting the fact that DHA, but
not EPA, lowers blood pressure [17].
More recently, Ulven et al. [15], compared the uptake
of n-3 LC PUFA in the form of TAG from fish oil to krill
oil in a randomized, parallel group study over 7 weeks,
and used total plasma FA composition as an endpoint.
Although the EPA+DHA doses used were different (543
mg in krill oil, 864 mg in fish oil), changes in total plasma
Table 2 Plasma phospholipid EPA, DHA, and total n-3 FA levels (mean ± standard deviation, % of total FAs) at
baseline and 24 h after ingestion of supplements
Baseline (%) After 24 h (%)
Fatty acids rTAG EE Krill oil rTAG EE Krill oil
EPA 0.92 ± 0.34 0.94 ± 0.30 0.79 ± 0.25 1.68 ± 0.30 1.82 ± 0.38 1.80 ± 0.36
DHA 2.61 ± 0.23 2.71 ± 0.64 2.56 ± 0.60 3.00 ± 0.52 2.90 ± 0.63 3.03 ± 0.48
EPA+DHA 3.53 ± 0.93 3.66 ± 0.77 3.35 ± 0.80 4.68 ± 0.52 4.72 ± 0.65 4.83 ± 0.59
total n-3 FA 4.70 ± 1.14 4.82 ± 0.98 4.38 ± 0.87 5.89 ± 0.55 5.93 ± 0.63 5.98 ± 0.63
Abbreviations: rTAG: re-esterified triacylglycerides; EE: ethyl esters
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FA and in a plasma lipid panel were similar. Although,
again, differences in dose obviate clear conclusions on
bioavailability, the data indicates that absorption of EPA
+DHA from krill oil was superior to fish oil TAG, which
would be in keeping with our results.
While the studies from Maki et al. [14] and Ulven et
al. [15] analyzed total plasma FA composition, we used
changes in plasma PL FA composition after a single
dose treatment as a proxy for bioavailability. There is
some disagreement as to what parameter reflects the
best bioavailability of LC n-3 FA. In terms of LC n-3
FA, red blood cells reflect tissue composition, at least of
the heart, but probably also of other organs [18]. It
remains to be demonstrated whether our findings can
be reproduced in a longer study focusing on red blood
cell FA composition, e.g. by using the omega-3 index.
Table 3 Plasma phospholipid EPA, DHA, and total n-3 FA levels (mean ± standard deviation, AUC [%*h], cmax [%] and
tmax [t]) 72 h after ingestion of supplements
rTAG EE Krill oil p *
EPA 37.05 ± 15.97 38.68 ± 18.60 53.62 ± 17.31 0.057
AUC [%*h] DHA 22.73 ± 26.23 8.85 ± 22.57 26.41 ± 29.54 0.246
EPA+DHA 59.78 ± 36.75 47.53 ± 38.42 80.03 ± 34.71 0.119
total n-3 FA 66.35 ± 37.53 49.49 ± 46.88 88.40 ± 42.81 0.134
EPA 0.98 ± 0.26 0.79 ± 0.51 1.18 ± 0.45 0.095
cmax [%] DHA 0.42 ± 0.48 0.21 ± 0.18 0.40 ± 0.41 0.323
EPA+DHA 1.12 ± 0.66 0.72 ± 0.76 1.51 ± 0.69 0.039
total n-3 FA 1.44 ± 1.06 0.73 ± 0.76 1.44 ± 0.89 0.110
EPA 11.5 ± 7.6 10.2 ± 8.6 7.8 ± 5.8 0.500
tmax [h] DHA 5.0 ± 6.2 9.8 ± 20.6 4.2 ± 6.6 0.538
EPA+DHA 10.5 ± 10.2 9.0 ± 9.2 7.1 ± 6.0 0.649
total n-3 FA 16.2 ± 20.2 9.0 ± 9.2 8.0 ± 8.2 0.307
Abbreviations: rTAG: re-esterified triacylglycerides; EE: ethyl esters; AUC: area under the curve.
* ANOVA.
Figure 1 Increase of n-3 FA concentrations in plasma PL after the ingestion of supplements. Healthy young males received n-3 FA as fish
oil rTAG (solid line), EE (dash line), or krill oil (dash dot line) supplements in a crossover manner. Results show change of EPA, DHA, EPA+DHA,
and total n-3 FA levels in plasma PL (% of total FAs, mean ± standard deviation) from baseline concentrations over 72 h.
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The mechanisms underlying the larger incorporation of
EPA+DHA from krill oil into plasma PL remain unknown
and might be due to several reasons. First of all, it was
rather surprising that the used krill oil contained a
remarkable amount of EPA (22% of total EPA amount)
and DHA (21% of total DHA amount) as FFA. It is
assumed that the rest of EPA (78%) and DHA (79%) in the
krill oil sample is bound to phospholipids, while only neg-
ligible contents are bound in TAGs. So far it was generally
accepted that EPA and DHA from krill oil is predomi-
nantly bound in PL. The unexpected high content of FFA
in krill oil might improve the bioavailability of EPA+DHA
from krill oil. A greater EPA or DHA bioavailability of
FFA compared to rTAG or EE, respectively, has been
shown in earlier studies [8,9,19], whereas Dyerberg et al.
[7] found the EPA+DHA bioavailability from FFA to be
equivalent to natural TAGs. Likewise, a recent study
demonstrated a markedly enhanced bioavailability of n-3
FFA over EE in overweight patients on a low-fat diet,
which is recommended for patients with hypertriglyceride-
mia [20].
On the other hand, the major proportion of EPA+DHA
in krill oil is bound in PL, and the intestinal absorption
of PL bound FA might be more efficient compared to
rTAG and EE. The digestion of FA esterified as PL is car-
ried out mainly by pancreatic phospholipase A2 (pPLA2)
and other pancreatic lipases. pPLA2 interacts with PL at
the sn-2 position yielding FFA and lyso-phosphatidylcho-
line, which are absorbed by the enterocytes as parts of
mixed micelles [21]. PL exhibit an amphiphilic character
and therefore emulsification properties. As a result, PL
influence the surface composition of fat droplets, which
possibly facilitates the binding of hydrolyzing enzymes
and hence the digestion [22]. Similarly, their presence is
essential for the formation of mixed micelles. It is possi-
ble that higher contents of PL support this formation
process, leading to an enhanced absorption of lipids. The
activities of other PL hydrolyzing lipases are likely to play
a meaningful role in the digestion of PL. Studies with
pPLA2-KO mice indicates that pPLA2 deficiency does
not affect PL hydrolysis and absorption in contrast to
TAG [23], possibly because its activity is compensated by
other PL hydrolyzing enzymes [24]. Thus the hydrolyzing
capacity of these lipases might also contribute to an effi-
cient digestion of dietary LC n-3 FA PL.
After absorption into enterocytes, the metabolism of LC
PUFA involves re-esterification into TAG (2-monoglyceride
pathway) and PL (a-glycerophosphate pathway), as well as
the formation of chylomicrons for further transport [25,26].
It can only be speculated if the higher EPA+DHA plasma
PL responses after krill oil ingestion is a result of an intensi-
fied incorporation of EPA+DHA into PL in consequence of
an increased presence of lyso-phosphatidylcholine. Further-
more PL are required for the formation of chylomicrons,
which could be another pathway facilitating the transport
of EPA+DHA in the circulating blood. A better under-
standing of the re-esterification LC PUFA to form TAG
and PL, as well as the following integration into lipopro-
teins requires further investigation.
Strengths and Limitations
Strengths: Almost identical doses of EPA+DHA were used
among treatments and the study had a straightforward
design. Recently, we demonstrated substantial inter-indivi-
dual variability in bioavailability of a TAG form of EPA
+DHA in a convenience drink [27]. The effect of inter-
individual variability is minimized by our randomized
crossover study design, while previous studies largely used
randomized parallel designs. Limitations: Despite the study
design, we observed high standard deviation values and
hence no significant differences in plasma PL FA composi-
tions between groups. Furthermore, the study was a single-
dose trial yielding no data on safety and tolerability.
Further studies with a larger sample size carried out over a
longer period are necessary to substantiate our findings. To
match the EPA, DHA and total n-3 FA intake, it was
necessary to increase the krill oil capsule intake. Hence the
subjects treated with krill oil ingested slightly more fat
compared to rTAG and EE (approximately one tenth more
in total), which could potentially bias our results. Finally,
plasma PL is not representative for tissue, a disadvantage
that has been already discussed.
Conclusion
By comparing plasma PL FA compositions in response
to almost identical doses of EPA+DHA in different che-
mical forms (rTAG vs. EE [both derived from fish oil]
vs. krill oil), we demonstrated that EPA+DHA were
absorbed in the following order: krill oil > rTAG > EE.
While this is the first study to report these differences
in bioavailability after oral administration, the study is
limited by an endpoint that is not representative for tis-
sue composition. In future long-term studies, such a
parameter should be addressed (e.g. the omega-3 index),
together with parameters representative for the biologi-
cal effects of EPA+DHA, such as serum TAG levels,
blood pressure and others. Addressing these issues
seems important in order to make the use of marine n-
3 FA more efficient. Finally, the unexpected high con-
tent of free EPA and DHA in krill oil, which might have
a significant influence on the bioavailability, should be
investigated in more depth and taken into consideration
in future trials.
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